These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 16272627

  • 21. [Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].
    Masho Y, Shigematsu T.
    Clin Calcium; 2007 Mar; 17(3):354-9. PubMed ID: 17339739
    [Abstract] [Full Text] [Related]

  • 22. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
    De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E.
    Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
    [Abstract] [Full Text] [Related]

  • 23. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M.
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [Abstract] [Full Text] [Related]

  • 24. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM, Radcliffe JS, White KE, Gattone VH, Seifert MF, Chen X, Aldridge B, Chen NX.
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [Abstract] [Full Text] [Related]

  • 25. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [Abstract] [Full Text] [Related]

  • 26. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.
    Tokumoto M, Mizobuchi M, Finch JL, Nakamura H, Martin DR, Slatopolsky E.
    Am J Nephrol; 2009 Apr; 29(6):582-91. PubMed ID: 19145073
    [Abstract] [Full Text] [Related]

  • 27. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M, Fukazawa S, Yasuda T, Akatsuka T, Tozawa S, Niida Y, Hashimoto N, Mochizuki T, Koike T.
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [Abstract] [Full Text] [Related]

  • 28. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model.
    Terai K, Mizukami K, Okada M.
    Nephrology (Carlton); 2008 Apr; 13(2):139-46. PubMed ID: 18275502
    [Abstract] [Full Text] [Related]

  • 29. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
    Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M.
    Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
    [Abstract] [Full Text] [Related]

  • 30. Sevelamer hydrochloride suppresses proliferation of parathyroid cells during the early phase of chronic renal failure in rats.
    Xiao X, Liu Y, Zhong X, Liu Y, Zhou D, Xiong X, Ran J.
    Nephrology (Carlton); 2019 Jan; 24(1):127-133. PubMed ID: 29278442
    [Abstract] [Full Text] [Related]

  • 31. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J, Liu S, Quarles LD.
    Semin Dial; 2007 Jan; 20(4):302-8. PubMed ID: 17635819
    [Abstract] [Full Text] [Related]

  • 32. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N, Miyata M, Sato N, Mochizuki T, Koike T.
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [Abstract] [Full Text] [Related]

  • 33. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
    Yokoyama T, Onodera Y, Mano T.
    Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
    [Abstract] [Full Text] [Related]

  • 34. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Sep; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 35. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
    Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM.
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
    [Abstract] [Full Text] [Related]

  • 36. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT.
    Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
    [Abstract] [Full Text] [Related]

  • 37. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [Abstract] [Full Text] [Related]

  • 38. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X, Yu L, Asuncion F, Grisanti M, Alexander S, Hensley K, Han CY, Niu QT, Dwyer D, Villasenor K, Stolina M, Dean C, Ominsky MS, Ke HZ, Tomlinson JE, Richards WG.
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [Abstract] [Full Text] [Related]

  • 39. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM.
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [Abstract] [Full Text] [Related]

  • 40. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M, Fukagawa M.
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.